A

TLANTA — If you want to avoid shingles — a condition that comes with a painful rash — there is a vaccine available. But studies have shown that protection generated by the vaccine declines quickly.

A new vaccine, however, is being considered for approval, and if and when the Food and Drug Administration gives it the green light, its may hit the market with a highly desirably preferential rating from an influential panel of vaccine experts.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Reply to JRH Cancel reply

Please enter your name.
Please enter a comment.

  • ““A preferential recommendation will make a difference here,” Bresnitz told the committee. “Let the market determine what happens here.”

    Translation: Let marketing, not the data, decide.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.